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Understanding the molecular pathogenesis of Parkinson’s dis-
ease (PD) is a priority area in biomedical research. It is a
pre-requisite to developing disease-modifying strategies and to
improve early diagnosis of disease. Over the last two decades,
geneticists have identified several genes underlying PD. Some of
these gene changes segregate with Mendelian forms of the dis-
ease. Others were identified as genetic risk factors of sporadic PD
via genome-wide association studies (GWAS).
Interestingly, a number of PD proteins have enzymatic func-
tions, including kinase, GTPase or ATPase activity. As enzymes are
often key elements in the regulation of cellular signaling networks,
they themselves or additional pathway components might pro-
vide new therapeutic targets for disease modifying therapies. For
instance, kinases mediate phosphorylation events, which activate
or inactivate their substrates, while GTPases modulate activity of
their effector proteins via direct interaction in a GDP/GTP depen-
dent manner. ATPases also control cellular processes through
their involvement in cellular energy production and/or in trans-
membrane transport. Finally, as is typical in cellular signaling
networks, enzymes are themselves not generally constitutively
active, but rather they are subject to regulation. Knowledge of how
PD kinases, GTPases, and ATPases are activated or inactivated can
aid in understanding how signaling networks are deregulated in
PD and can also point to new therapeutic targets. This special
Research Topic of Frontiers in Molecular Neuroscience discusses
new key knowledge on the regulation and targeting of kinases,
GTPases and ATPases in PD and presents new original research in
this field.
The PD enzymes discussed in this Research Topic were discov-
ered either in genetic linkage or genetic association studies (www.
genenames.org/genefamilies/PARK, www.pdgene.org, Lill et al.,
2012) or in biological studies revealing a strong functional link
with one of the PD proteins. In this context, PD enzymes are
the ATPase ATP13A2 encoded by a gene at the PARK9 locus, sev-
eral GTPases, including the small GTPase RAB7L1, and leucine-
rich repeat kinase 2 (LRRK2) which functions as a kinase and
GTPase (Greggio, 2012; Taymans, 2012). Several PD proteins are
kinases including Pten-induced kinase 1 (PINK1) and LRRK2,
discovered in genetic linkage studies in familial PD patients. In
addition, LRRK2 and cyclin G associated kinase (GAK) were
identified in genetic association studies in sporadic PD sufferers.
Importantly, the pathogenicity of some gene products of PD genes
is also regulated by phosphorylation by upstream kinases, such as
polo-like kinase 2 (PLK2), which phosphorylates the PD protein
α-synuclein. There are also multiple kinases phosphorylating the
microtubule associated protein tau (MAPT), a protein known to
be involved in Alzheimer’s disease and associated to PD in GWAS
(Lill et al., 2012).
Van Veen et al. review the cellular function and pathologi-
cal role of ATP13A2 and related P-type transport ATPases in PD
and other neurological disorders (Van Veen et al., 2014). P-type
ATPases are transmembrane transporters, which use energy from
ATP hydrolysis to transport substrates across membranes and
against their concentration gradients. The authors provide an
overview of this family of proteins and their molecular and bio-
chemical features. An overview is also given of the involvement of
P-type ATPases in multiple neurological disorders. They specifi-
cally elaborate on ATP13A2, which causes a severe form of early
onset Parkinsonism known as Kufor-Rakeb syndrome.
Rivero-Ríos et al. review the evidence pointing to the upstream
deregulation of calcium signaling in Parkinson’s disease (Rivero-
Ríos et al., 2014). Ca2+ is not only an important secondary
messenger in cellular signaling, but is also essential for the proper
functioning of multiple cellular organelles. The authors discuss
the role of PD genes in the regulation of Ca2+ homeostasis as
well as the potential therapeutic strategies to slow PD progression
based on counteracting abnormal Ca2+ handling.
When studying kinases involved in disease processes, a com-
mon pathomechanism is hyperphosphorylation of substrates. In
their review, Tenreiro et al. explore the phosphorylation of two
important proteins in PD, namely α-synuclein and tau (Tenreiro
et al., 2014). A-synuclein is a key protein in PD, as it is a main
component of the defining pathological feature of PD, Lewy bod-
ies, and genetic variants of α-synuclein are linked with familial PD
and associated with sporadic PD. Interestingly, phosphorylation
of one key residue (serine 129) is associated with PD pathology.
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By contrast, tau contains multiple phosphorylation sites associ-
ated with disease, and is known to be involved in AD, although
it also contributes to some forms of Parkinsonism. Another
common feature of cellular functioning of kinases is that often
multiple kinases functionally interact with each other in signaling
networks. Related to this, Matenia and Mandelkow discuss recent
work revealing an association of PINK1 with the microtubule
associated kinase MARK2 which is involved in axonal transport
(Matenia and Mandelkow, 2014).
Arguably, LRRK2 is one of the most important proteins
involved in PD, and this is reflected by the number of papers
on LRRK2 in this Research Topic. Gilsbach and Kortholt review
the available structural biology data on homologs of LRRK2
(Gilsbach and Kortholt, 2014). The structure of other members of
this Ras of complex proteins (ROCO) family has potential impli-
cations for LRRK2 functioning. Indeed, ROCO proteins from
lower organisms such as bacteria and slime molds have yielded
atomic structure data, which has begun to reveal mechanistic
insight in the functioning of this poorly known family of pro-
teins. The authors focus on structures of the ROCO GTPase and
kinase domains. Although there is a good degree of structural and
functional heterogeneity between different ROCO proteins, the
recently elucidated ROCO structures are suggestive of common
mechanisms for ROCO proteins, which can be tested for LRRK2
in the future. In the absence of structures for human LRRK2, the
combination of these data withmolecularmodels of LRRK2 (such
as the optimized human LRRK2 kinase domain model presented
in another paper of this issue, Vancraenenbroeck et al., 2014)
can provide insight into the structural underpinnings of LRRK2
functions.
Boon et al. (2014) discuss aspects of LRRK2 as a regulator of
cellular signaling, with a focus on reported interactions of LRRK2
with MAPK signaling cascades, GTPases and GTPase regulating
proteins. This paper also discusses the key issues in LRRK2 biol-
ogy to link biochemical activity of LRRK2 to cell biological effects
(Boon et al., 2014). Related to this, Cirnaru et al. report original
research showing that LRRK2 kinase activity regulates synaptic
vesicle trafficking and neurotransmitter release through modula-
tion of LRRK2macro-molecular complexes (Cirnaru et al., 2014).
The LRRK2 kinase activity is currently regarded as a potential
therapeutic target, however several issues remain, most specif-
ically in how to monitor this activity in cell culture. Related
to this is the fact that LRRK2 is itself a phosphorylated pro-
tein (Gloeckner et al., 2010; Lobbestael et al., 2012). The LRRK2
phosphorylation sites are potential correlates for LRRK2 activity.
Reynolds et al. (2014) provide an extensive study characterizing in
parallel multiple autophosphorylation and cellular phosphoryla-
tion sites and explore how the regulation of these sites correlates
to LRRK2 kinase activity and biology. Vancraenenbroeck et al.
studied another aspect of LRRK2 cellular phosphorylation by
using a kinome-wide panel of kinase inhibitors to identify com-
pounds that regulate LRRK2 phosphorylation levels. This type of
approach is designed to inhibit upstream kinases phosphorylat-
ing LRRK2 and compounds that lead to dephosphorylation are
expected to point to these upstream kinases. The correlation of
cellular activity with the in silico and in vitro analysis of the kinase
inhibitors shows that the strongest dephosphorylation of LRRK2
is induced by compounds which act on LRRK2 itself, without
excluding a role for upstream kinases (Vancraenenbroeck et al.,
2014).
Kinases are a very attractive class of drug targets in general
and much expertise has been built up from the development of
kinase inhibitors for the treatment of cancers. Kinase inhibitors
have a relatively low attrition rate in development compared to
compounds directed toward other classes of targets and several
kinase inhibitors are now in routine clinical practice, mostly in
the field of oncology. Developing small compounds to modulate
GTPase activities on the other hand is a path much less traveled.
Given the number of potential GTPase targets for the treatment
of PD, including LRRK2 (Taymans, 2012) or RAB7L1 (Beilina
et al., 2014), approaches to discover and develop drugs modu-
lating GTPases merit further investigation. In their review, Hong
and Sklar (2014) discuss several GTPases which may be targeted
for PD therapy and suggest approaches for GTPase drug discov-
ery. Finally, to have a full overview of kinases involved in PD,
it is important to have an understanding of their brain expres-
sion patterns. This subject is extensively reviewed by Dzamko
et al. (2014) for a number of PD kinases, including LRRK2, GAK,
and PLK2.
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